The US Securities and Exchange Commission (SEC) has defended its settlement agreement with Elon Musk over his acquisition of Twitter shares, stating that the agreement reflects a "compromise between both parties" and denying any suspicion of collusion.

The US Securities and Exchange Commission (SEC) has defended its settlement agreement with Elon Musk over his acquisition of Twitter shares, stating that the agreement reflects a "compromise between both parties" and denying any suspicion of collusion.

老虎证券2026/06/02 00:08

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Previously, the judge presiding over the case had stated that the agreement raised a "red flag." In documents submitted to the federal court in Washington, D.C., the SEC also noted in a footnote that, if the settlement agreement is approved, it would allow Musk to publicly deny the relevant allegations. This reflects a recent policy change concerning defendants entering into enforcement settlements. The settlement agreement requires the establishment of a trust fund in Musk's name, with a payment of $1.5 million, to resolve the SEC's allegations that the world's richest man delayed disclosure of his purchase of Twitter shares by 11 days in March and April 2022, allowing him to buy at a lower price before investors became aware. Musk stated that the delay in disclosure was unintentional. He eventually acquired Twitter for $44 billion in October 2022 and renamed it X. In Monday's filing, the SEC stated that this "fair, reasonable, and appropriate" settlement agreement is "not the result of any improper collusion between the parties" but "arose from fair negotiations between attorneys of record and reflects a compromise between the two sides." The agency also emphasized that the $1.5 million fine is the largest in similar cases and that settling with the trust fund is consistent with the SEC's recent practices in similar cases.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

On October 8, Revolution Medicines (RVMD.O) shares fell 8.1% in afternoon trading to $185.91. RBC Capital Markets stated that the share price decline appeared to be driven by the latest U.S. Food and Drug Administration (FDA) review documents regarding the company's pancreatic cancer drug Rasonque, particularly the disclosure of objective response rate data for specific RAS mutation subgroups. RBC pointed out that overall survival, rather than objective response rate, is a more meaningful indicator of efficacy, and that the sell-off overlooked Rasonque's broad activity across a variety of RAS mutation subgroups. RBC stated: "While we acknowledge that today's share price decline takes place against the backdrop of overall weakness in the biotech sector, we still believe that the market's reaction to the FDA review documents is an overreaction, given that the drug was approved on the basis of highly clinically meaningful efficacy and has received positive feedback from physicians." Including intraday fluctuations, the stock has more than doubled year-to-date. (Note: For the convenience of non-English speakers, Reuters has automatically translated its reports into several other languages. Automated translations may be inaccurate or lack necessary context; Reuters does not guarantee the accuracy of these automated translations and provides them only for reader convenience. Reuters does not accept liability for any damage or loss arising from the use of automated translation features.)

路透社•2026/10/08 18:26